Enterprise Value
150.7M
Cash
93.01M
Avg Qtr Burn
-15.47M
Short % of Float
1.37%
Insider Ownership
53.88%
Institutional Own.
17.26%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PI-2620 Details Neurological disorder, Alzheimer's disease | Phase 3 Data readout | |
Semorinemab Details Neurological disorder, Alzheimer's disease | Phase 2 Data readout | |
Crenezumab Details Neurological disorder, Alzheimer's disease | Phase 2 Update | |
ACI-7104.056 Details Parkinson's disease | Phase 2 Update | |
ACI-24.060 (anti-Abeta vaccine) Details Neurological disorder, Alzheimer's disease, Down Syndrome | Phase 1/2 Data readout | |
ACI-35.030 (anti-pTau vaccine) or JACI-35.054 Details Neurological disorder, Alzheimer's disease | Phase 1/2 Initiation | |
AC1-3024 Details Neurological disorder | Failed Discontinued |